+91-9896593699

DRDEEPAKSHUKLA https://www.cancerinfo.in
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

919896539256

EGFR mutation testing is essential part of work up of advanced NSCLC.Based on a paper puplished in 2015 looking into trends of EGFR mutation analysis in clinical practice, it was noted that EGFR genetic testing was not conducted in 19% of advanced

ERA OF PERSONALISED MEDICINE IN METASTATIC ADENOCARCINOMA LUNG:Stage IV adenocarcinoma is not a single disease. Different molecular subtypes of NSCLC have been identified and the treatment approach is different for each subtype.The different mole

Liquid biopsy in non small cell lung cancer is now being used for detection of EGFR mutation analysis in patients who do not have accessible tissue for conventional testing and based on the platform used for liquid biopsy ie digital v/s nondigital it

Decoding Lynch syndrome -- Colorectal cancer(CRC)Lynch syndrome is the most common cause of inherited Colorectal cancer (CRC-large intestine cancer). It constitutes 3% of all newly diagnosed colorectal cancer burden.In lynch syndrome there is ger

Maintenance with PARP inhibitor is the way forward in ovarian cancer:Median PFS in platinum sensitive relapse carcinoma ovary is approximately 10 months.20% of high grade serous carcinoma ovary have somatic or germline mutation in BRCA gene.Sin

Redefining low grade glioma ( a type of brain tumor ) using WHO 2016 classification:Clinical presentation of low grade glioma is usually with new onset seizureRadiologically low grade glioma are hyperintense on T2 MRI images and do not show contr

CML (chronic myeloid leukemia) is a cancer that affects bone marrow and blood.The diagnosis of CML is confirmed by presence of Philadelphia chromosome on cytogenetics or FISH or by detecting bcr-abl by PCR.It has 3 phases chronic, accelerated and b

Targeted therapy with gefitinib or erlotinib for 2 years is better than chemotherapy as adjuvant in resected non small cell lung cancer stage l to llla with EGFR mutation. The result suggest better disease free survival, however overall survival data

services